Elevidys Helps Sarepta To First US FDA Platform Technology Designation

 
• By Bridget Silverman
  
The FDA's platform technology designation for Sarepta's rAAVrh74 vector could boost its pipeline of gene therapies for limb-girdle muscular dystrophies. (Shutterstock)

More from Platform Technologies

More from Rare Diseases